Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide

被引:11
|
作者
Boytsov, Natalie [1 ]
Zhang, Xiang [1 ]
Sugihara, Tomoko [2 ]
Taylor, Kathleen [1 ]
Swindle, Ralph [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] InVentiv Hlth Clin, Princeton, NJ USA
关键词
Comparative effectiveness; Healthcare resource utilization; Osteoporosis; Teriparatide; BONE-MINERAL DENSITY; PERSISTENCE; ADHERENCE; SCORE;
D O I
10.1185/03007995.2015.1066765
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare fractures and fracture-related resource utilization (RU) among patients with a recent fracture and treated with teriparatide (TPTD) to a matched cohort of patients not treated with TPTD (non-TPTD). Research design and methods: Women aged 50 years or older initiating TPTD (N = 5314; index date between 1 January 2007 and 31 December 2012) were identified in an insurance claims database. Patients with fragility fracture (hip, pelvis, clavicle, humerus, wrist, leg or spine) during the 12 months prior to the index date (N = 1164) were selected to control for unmeasured confounding due to absence of bone mineral density test levels. TPTD patients were matched to the non-TPTD cohort using propensity score and exact matching (N = 912). Relative risk (RR) of fracture and fracture-related RU were estimated by Cox proportional hazard modeling, adjusted for potential fracture risk factors. Results: Fractures were observed in 4.6%, 8.6%, 10.3%, and 11.3% of TPTD patients and in 9.2%, 15.2%, 19.2% and 21.7% of non-TPTD patients over 6, 12, 18, and 24 months, respectively. The adjusted RR reduction in TPTD was 36% (RR = 0.64, 95% CI: 0.44-0.94) during 6 months, 27% (RR = 0.73, 95% CI: 0.54-0.97) during 12 months, 28% (RR = 0.72, 95% CI: 0.55-0.93) during 18 months, and 28% (RR = 0.72, 95% CI: 0.56-0.92) during 24 months versus matched non-TPTD patients. Fracture-related RU followed a similar trend to that observed for fracture risk. Conclusions: This real-world study found TPTD to be more effective in reducing risk of fragility fractures as early as 6 months with continuous treatment benefit up to 24 months compared to a matched non-TPTD cohort. TPTD patients experienced lower rates of fracture-related RU than non-TPTD patients. Key study limitations include the inability to confirm reported diagnostic and procedural codes and the absence of uninsured and individually insured patients in the claims database.
引用
收藏
页码:1665 / 1675
页数:11
相关论文
共 50 条
  • [1] SUBUNGUAL EXOSTOSIS IN AN OSTEOPOROTIC PATIENT TREATED WITH TERIPARATIDE
    Delivanis, Danae A.
    Bhargava, Amit
    Luthra, Pooja
    [J]. ENDOCRINE PRACTICE, 2013, 19 (05) : E115 - E117
  • [2] ADHERENCE IN PATIENTS WITH SEVERE OSTEOPOROSIS TREATED WITH TERIPARATIDE
    Ziller, V.
    Zimmermann, S-P.
    Ziller, M.
    Hadji, P.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 34 - 34
  • [3] PINP as an aid for monitoring patients treated with teriparatide
    Tsujimoto, Mika
    Chen, Peiqi
    Miyauchi, Akimitsu
    Sowa, Hideaki
    Krege, John H.
    [J]. BONE, 2011, 48 (04) : 798 - 803
  • [4] Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide
    Miller, Paul D.
    Bilezikian, John P.
    Diaz-Curiel, Manuel
    Chen, Peiqi
    Marin, Fernando
    Krege, John H.
    Wong, Mayme
    Marcus, Robert
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09): : 3535 - 3541
  • [5] Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates
    Watts, Nelson B.
    Aggers, Deborah
    McCarthy, Edward F.
    Savage, Tina
    Martinez, Stephanie
    Patterson, Rachel
    Carrithers, Erin
    Miller, Paul D.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (05) : 1027 - 1033
  • [6] Teriparatide treatment in osteoporotic patients treated with glucocorticoids for chronic inflammatory/autoimmune rheumatic diseases
    La Corte, R.
    Limpido, G.
    Volpinari, S.
    Trotta, F.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S324 - S324
  • [7] Femoral strength in osteoporotic women treated with teriparatide or alendronate
    Keaveny, Tony M.
    McClung, Michael R.
    Wan, Xiaohai
    Kopperdahl, David L.
    Mitlak, Bruce H.
    Krohn, Kelly
    [J]. BONE, 2012, 50 (01) : 165 - 170
  • [8] Early efficacy of teriparatide in multilevel osteoporotic vertebral compression fractures treated by percutaneous vertebroplasty
    Doria, C.
    Lisai, P.
    Milia, F.
    Tidu, L.
    Tranquilli, Leali P.
    Meloni, G. B.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S255 - S255
  • [9] Use of teriparatide in osteoporotic fracture patients
    Collinge, Cory
    Favela, Juan
    [J]. INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2016, 47 : S36 - S38
  • [10] Adherence and persistence in patients with severe osteoporosis treated with teriparatide
    Ziller, V.
    Zimmermann, S. P.
    Kalder, M.
    Ziller, M.
    Sekar-Pektas, B.
    Hellmeyer, L.
    Hadji, P.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (03) : 675 - 681